NKGen Expands Alzheimer’s Trial to Canada, Florida

NKGen Biotech has activated two new clinical trial sites for its Phase I/IIa study of troculeucel, a cryopreserved expanded autologous natural killer (NK) cell therapy targeting moderate Alzheimer's disease. The new sites, Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, are now open for patient enrollment following clearance from Health Canada, allowing Canadian patient participation. The Ottawa Memory Clinic, led by renowned neuroscientist Dr. Richard Bergeron, a specialist in neurodegenerative diseases with extensive clinical trial experience, will enhance the trial's scientific expertise and patient diversity. AdventHealth Orlando, under Dr. Anita Fletcher, strengthens the trial’s footprint on the U.S. East Coast, facilitating broader patient access and accelerating recruitment. Site activation involved comprehensive preparations such as staff training and protocol setup, which are essential to ensure the trial progresses as planned. This expansion marks a strategic step in NKGen's commitment to developing innovative treatments for Alzheimer's disease and advancing the commercialization of troculeucel.